<DOC>
	<DOCNO>NCT02977013</DOCNO>
	<brief_summary>The aim present study monitor anticoagulant therapy anti-Xa assay correlate level efficacy safety enoxaparin treatment pulmonary embolism .</brief_summary>
	<brief_title>Anti-Xa Assay Correlation Efficacy Safety Enoxaparin Treatment Pulmonary Embolism</brief_title>
	<detailed_description>This prospective randomize trial conduct 42 patient 18 year age old ICU diagnose pulmonary embolism confirm presence intraluminal filling defect CT pulmonary angiography treat subcutaneous enoxaparin 1 mg/kg/12 hour . The study conduct August 2013 September 2016 . All patient examine daily period 4 week symptoms sign recurrent pulmonary embolism ( recurrent pulmonary embolism diagnose repeat CT angiography reveal new sudden arterial branch cutoff new intraluminal filling defect present first angiogram ) , Platelet count ( patient platelet count le 50,000/mm3 bleeding platelet count 50,000 100,000/mm3 consider severe thrombocytopenia ) , bleed ( defined major overt bleed require blood transfusion &gt; 2 unit mark hemoglobin drop &gt; 2 gm/dl bleed intracranial retroperitoneal ) death ( defined death occur within 4 week study ) , Then result correlate anti-Xa assay .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<criteria>Patients ICU diagnose pulmonary embolism confirm presence intraluminal filling defect CT pulmonary angiography treat subcutaneous enoxaparin 1 mg/kg/12 hour . Patients underwent thrombolysis , embolectomy unfit anticoagulant therapy major bleed thrombocytopenia ( platelet count 100,000 per cubic millimeter ) . Patients also exclude impaired kidney function serum creatinine level 2 mg/dl uncontrolled hypertension ( blood pressure &gt; 160/100 mmHg ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>